CA2481466A1 - Depsipeptide pour la therapie du cancer du rein - Google Patents
Depsipeptide pour la therapie du cancer du rein Download PDFInfo
- Publication number
- CA2481466A1 CA2481466A1 CA002481466A CA2481466A CA2481466A1 CA 2481466 A1 CA2481466 A1 CA 2481466A1 CA 002481466 A CA002481466 A CA 002481466A CA 2481466 A CA2481466 A CA 2481466A CA 2481466 A1 CA2481466 A1 CA 2481466A1
- Authority
- CA
- Canada
- Prior art keywords
- formula
- compound
- kidney cancer
- salt
- therapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/15—Depsipeptides; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne un agent thérapeutique du cancer du rein, à base du FK228 représenté par la formule générale (I), ou de l'un de ses sel. En l'occurrence, ce FH228, ou le sel considéré, qui constituent le principe actif de la présente invention, font preuve, in vivo, d'une activité antitumorale accrue contre le cancer du rein.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36986802P | 2002-04-05 | 2002-04-05 | |
US60/369,868 | 2002-04-05 | ||
PCT/JP2003/003823 WO2003084611A1 (fr) | 2002-04-05 | 2003-03-27 | Depsipeptide pour la therapie du cancer du rein |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2481466A1 true CA2481466A1 (fr) | 2003-10-16 |
Family
ID=28791999
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002481466A Abandoned CA2481466A1 (fr) | 2002-04-05 | 2003-03-27 | Depsipeptide pour la therapie du cancer du rein |
Country Status (9)
Country | Link |
---|---|
US (1) | US8673888B2 (fr) |
EP (1) | EP1492596A1 (fr) |
JP (1) | JP2005521737A (fr) |
CN (1) | CN1649645A (fr) |
AU (1) | AU2003219555A1 (fr) |
CA (1) | CA2481466A1 (fr) |
MX (1) | MXPA04009761A (fr) |
TW (1) | TW200405817A (fr) |
WO (1) | WO2003084611A1 (fr) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2371630T3 (es) * | 2001-08-21 | 2012-01-05 | Astellas Pharma Inc. | Uso medicinal de un inhibidor de histona desacetilasa y método para evaluar su efecto antitumoral. |
CA2519320A1 (fr) * | 2003-02-19 | 2004-09-02 | Astellas Pharma Inc. | Procede d'evaluation de l'effet antitumoral d'un inhibiteur d'histone desacetylase |
US20050059682A1 (en) * | 2003-09-12 | 2005-03-17 | Supergen, Inc., A Delaware Corporation | Compositions and methods for treatment of cancer |
JP4779971B2 (ja) * | 2003-09-25 | 2011-09-28 | アステラス製薬株式会社 | ヒストンデアセチラーゼ阻害剤とトポイソメラーゼii阻害剤とからなる抗腫瘍剤 |
WO2005058298A2 (fr) * | 2003-12-10 | 2005-06-30 | Wisconsin Alumni Research Foundation | Analogues de fk228 et methodes de production et d'utilisation desdits analogues |
US7951780B2 (en) * | 2004-02-25 | 2011-05-31 | Astellas Pharma Inc. | Antitumor agent |
BRPI0613429A2 (pt) | 2005-07-14 | 2009-02-10 | Takeda San Diego Inc | inibidores de histona desacetilase |
JP2009519224A (ja) * | 2005-11-18 | 2009-05-14 | グロスター ファーマシューティカルズ, インコーポレイテッド | Hdacインヒビターfk228の代謝産物誘導体 |
WO2008013589A2 (fr) * | 2006-04-24 | 2008-01-31 | Gloucester Pharmaceuticals | Traitement de tumeurs exprimant ras |
US8957027B2 (en) * | 2006-06-08 | 2015-02-17 | Celgene Corporation | Deacetylase inhibitor therapy |
EP2124990A4 (fr) * | 2006-12-29 | 2010-04-21 | Gloucester Pharmaceuticals Inc | Traitements du cancer à base de romidepsine |
WO2008083288A2 (fr) * | 2006-12-29 | 2008-07-10 | Gloucester Pharmaceuticals | Préparation de la romidepsine |
US8034768B2 (en) * | 2007-06-22 | 2011-10-11 | Board Of Regents, The University Of Texas System | Composition and method for the treatment of diseases affected by histone deacetylase inhibitors |
RU2607634C2 (ru) | 2010-07-12 | 2017-01-10 | Селджин Корпорейшн | Твердые формы ромидепсина и их применение |
US8859502B2 (en) | 2010-09-13 | 2014-10-14 | Celgene Corporation | Therapy for MLL-rearranged leukemia |
AU2013202506B2 (en) | 2012-09-07 | 2015-06-18 | Celgene Corporation | Resistance biomarkers for hdac inhibitors |
AU2013202507B9 (en) | 2012-11-14 | 2015-08-13 | Celgene Corporation | Inhibition of drug resistant cancer cells |
NZ630311A (en) | 2013-12-27 | 2016-03-31 | Celgene Corp | Romidepsin formulations and uses thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8817743D0 (en) * | 1988-07-26 | 1988-09-01 | Fujisawa Pharmaceutical Co | Fr901228 substance & preparation thereof |
JPH0764872A (ja) | 1993-08-26 | 1995-03-10 | Fujitsu Ten Ltd | データ記憶制御装置 |
WO2002006307A1 (fr) * | 2000-07-17 | 2002-01-24 | Fujisawa Pharmaceutical Co., Ltd. | Fk228 reduit et son utilisation |
AR035659A1 (es) * | 2000-12-07 | 2004-06-23 | Hoffmann La Roche | Hidroxiamidas de acido (1-oxo-1,2,3,4-tetrahidro-naftalen-2-il)-alcanoico, proceso para la manufactura de estos compuestos, composiciones farmaceuticas que contienen dichos compuestos y los usos de los mismos |
US6905669B2 (en) | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
ES2371630T3 (es) * | 2001-08-21 | 2012-01-05 | Astellas Pharma Inc. | Uso medicinal de un inhibidor de histona desacetilasa y método para evaluar su efecto antitumoral. |
WO2003017763A1 (fr) * | 2001-08-24 | 2003-03-06 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Emploi d'un inhibiteur d'histone deacetylase visant a augmenter la penetration d'un agent adenoviral dans une cellule |
DK2238982T3 (da) * | 2003-06-27 | 2013-01-28 | Astellas Pharma Inc | Terapeutisk middel til blødt væv-sarcom |
JP4779971B2 (ja) * | 2003-09-25 | 2011-09-28 | アステラス製薬株式会社 | ヒストンデアセチラーゼ阻害剤とトポイソメラーゼii阻害剤とからなる抗腫瘍剤 |
US7951780B2 (en) * | 2004-02-25 | 2011-05-31 | Astellas Pharma Inc. | Antitumor agent |
-
2003
- 2003-03-27 CN CNA038075938A patent/CN1649645A/zh active Pending
- 2003-03-27 CA CA002481466A patent/CA2481466A1/fr not_active Abandoned
- 2003-03-27 US US10/508,958 patent/US8673888B2/en active Active
- 2003-03-27 AU AU2003219555A patent/AU2003219555A1/en not_active Abandoned
- 2003-03-27 JP JP2003581847A patent/JP2005521737A/ja active Pending
- 2003-03-27 EP EP03715503A patent/EP1492596A1/fr not_active Withdrawn
- 2003-03-27 MX MXPA04009761A patent/MXPA04009761A/es not_active Application Discontinuation
- 2003-03-27 WO PCT/JP2003/003823 patent/WO2003084611A1/fr active Application Filing
- 2003-04-04 TW TW092107689A patent/TW200405817A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CN1649645A (zh) | 2005-08-03 |
WO2003084611A1 (fr) | 2003-10-16 |
EP1492596A1 (fr) | 2005-01-05 |
WO2003084611A8 (fr) | 2004-04-08 |
US20060135413A1 (en) | 2006-06-22 |
US8673888B2 (en) | 2014-03-18 |
MXPA04009761A (es) | 2005-05-27 |
AU2003219555A8 (en) | 2003-10-20 |
JP2005521737A (ja) | 2005-07-21 |
TW200405817A (en) | 2004-04-16 |
AU2003219555A1 (en) | 2003-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8673888B2 (en) | Depsipeptide for therapy of kidney cancer | |
JP4661782B2 (ja) | 軟部肉腫治療剤 | |
JP4930055B2 (ja) | 抗腫瘍剤 | |
EP2263694B1 (fr) | Agent antitumoral renfermant l'inhibiteur de l'histone désacétylase FK228 et l'inhibiteur de la topoisomerase-II, doxorubicine | |
JP4238728B2 (ja) | ヒストンデアセチラーゼ阻害剤の医薬用途ならびにその抗腫瘍効果の評価方法 | |
JP2008520682A (ja) | ヒストンデアセチラーゼ阻害剤およびその使用方法 | |
JP2010516767A (ja) | ロミデプシンおよびi.a.ボルテゾミブを含む併用療法 | |
JP3987909B2 (ja) | 新規なデプシペプチド化合物 | |
CN109796519B (zh) | 一类甾体化合物及其应用 | |
Flahive et al. | The dolastatins | |
KR20050016331A (ko) | 신장암 치료를 위한 뎁시펩티드 | |
MX2007005512A (es) | Inhibidores de deacetilasa de histona y metodos de uso | |
MXPA06009577A (en) | Antitumor agent | |
JP2009107928A (ja) | パウ・フェロから単離された新規化合物 | |
JP2005075741A (ja) | 放射線効果増強剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |